A new era of cancer screening is here with the Galleri® test

Leading life insurance companies are embracing innovation to detect cancer early. 

Introducing Galleri, the first-of-its-kind multi-cancer early detection test that looks for a signal shared by 50+ types of cancer with a single blood test.1

Play the video to learn about Rich's head and neck cancer story.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Rich testimonials

Play the video to learn about Rich's head and neck cancer story.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Time Magazine named Galleri
a best invention of 2022.1

“I think every company should be doing this...it would be wonderful for our industry to be perceived as an industry that isn't just there in death but helps people along the way.”

Brooks Tingle, President & CEO
John Hancock Insurance

Hear from industry leaders why they are partnering with GRAIL to offer Galleri to their clients.

Watch to learn more:
Video of the panel discussion with Galleri and Munich RE at the InsureTech Connect 2022 conference

Munich Re and John Hancock

Video interview of why the M Financial Group is partnering with GRAIL to offer Galleri to their clients.

M Financial Group

GRAIL + John Hancock Vitality

Bring Galleri to your clients today.

We're here to help.

Imagine if you could help your clients find cancer early enough to make a difference

Rich's head and neck cancer story

Rich always thought he was doing everything necessary to maintain his health, including undergoing recommended cancer screenings. However, everything changed after he learned about the Galleri test as a benefit from his Nationwide life insurance policy.

Roger testimonial

Roger's pancreatic cancer story

Roger's cancer diagnosis was the last thing he anticipated as someone who makes a point to lead an active and plant-based lifestyle. Now he wants to share the importance of early detection.


Valerie's gallbladder cancer story

Valerie took the Galleri test out of curiosity, Galleri detected a cancer signal and predicted the cancer signal origin of pancreas, gallbladder.

Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. Galleri should be used in addition to healthcare provider recommended screening tests.

How to take the Galleri test

The Galleri test looks for a signal associated with active cancer.

illustrated video depiction of how to take the Galleri test

Ready to Get Started?

Fill out this form to bring Galleri to your clients today.

We care about your privacy. Our Privacy Policy

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Withers, Ali. Earlier detection: Grail Galleri cancer test. The best Inventions of 2022.Time Magazine. [10 November 2022]. Available from: https://time.com/collection/best-inventions-2022/6225228/grail-galleri-cancer-test/.

  2. National Cancer Institute. What Is Cancer? https://www.cancer.gov/about-cancer/understanding/what-is-cancer.

  3. US Preventive Services Task Force Recommended Screenings. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.

  4. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.

  5. Schrag D, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.